Announcements Trials
Browse Landscape

Status

Completed 11Terminated 10Recruiting 7Active not recruiting 7Unknown 6Withdrawn 4Not yet recruiting 2No longer available 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1

Interventions

Amifampridine 4fludarabine phosphate 3gallium 68 PSMA-11 2fludarabine 2carbon-11 acetate 2Whole-Body Irradiation 2Magnetic Resonance Spectroscopy 2Ga(III)-DOTATOC 2Cyclophosphamide 23-Iodobenzylguanidine 2venetoclax 1veliparib 1ulocuplumab 1trametinib 1selinexor 1ponatinib 1pembrolizumab 1pegfilgrastim 1omburtamab I-131 1nirogacestat 1neratinib 1navitoclax 1ganitumab 1gallium Ga 68 dotatate 1fluorodopa F 18 1elotuzumab 1carfilzomib 1asparaginase erwinia chrysanthemi recombinant 1aldesleukin 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × OTHER × ponatinib × Clear all
NCT01549548 2013-03-15

Compassionate Use Ponatinib

OHSU Knight Cancer Institute

No longer available
MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡